Without oversight systems, phase IV trials will continue to be used by drug companies to market products without generating the information that clinicians and policy makers can use to improve care and maintain a more cost-effective health system. Efforts tied to the current focus of research ethics on protecting study participants fail to prevent problems that undermine the social value of research, according to bioethicists from Carnegie Mellon University in Pittsburgh, and McGill University in Montreal. Alex John London, Jonathan Kimmelman and Benjamin Carlisle argue that current research ethics frameworks do not flag drug trials that, while not putting patients at risk, produce biased evidence. Read more here.
Study mentioned: London AJ, et al. Research ethics. Rethinking research ethics: the case of postmarketing trials. Science. 2012 May 4;336(6081):544-5. PMID: 22556237
No comments:
Post a Comment